CL2015003357A1 - 4'-Fluoro-2'-methyl substituted nucleoside derivatives - Google Patents

4'-Fluoro-2'-methyl substituted nucleoside derivatives

Info

Publication number
CL2015003357A1
CL2015003357A1 CL2015003357A CL2015003357A CL2015003357A1 CL 2015003357 A1 CL2015003357 A1 CL 2015003357A1 CL 2015003357 A CL2015003357 A CL 2015003357A CL 2015003357 A CL2015003357 A CL 2015003357A CL 2015003357 A1 CL2015003357 A1 CL 2015003357A1
Authority
CL
Chile
Prior art keywords
fluoro
methyl substituted
substituted nucleoside
nucleoside derivatives
derivatives
Prior art date
Application number
CL2015003357A
Other languages
Spanish (es)
Inventor
Klaus G Klumpp
Mark Smith
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of CL2015003357A1 publication Critical patent/CL2015003357A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Abstract

COMPUESTOS NUCLEOSIDOS DERIVADOS SUSTITUIDOS DE 4'-FLUORO-2'-METIL; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DE HCV.SUBSTITUTED DERIVED NUCLEOSID COMPOUNDS OF 4'-FLUORO-2'-METIL; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR HCV TREATMENT.

CL2015003357A 2013-05-16 2015-11-13 4'-Fluoro-2'-methyl substituted nucleoside derivatives CL2015003357A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824030P 2013-05-16 2013-05-16

Publications (1)

Publication Number Publication Date
CL2015003357A1 true CL2015003357A1 (en) 2016-11-04

Family

ID=51895938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003357A CL2015003357A1 (en) 2013-05-16 2015-11-13 4'-Fluoro-2'-methyl substituted nucleoside derivatives

Country Status (23)

Country Link
US (1) US9895442B2 (en)
EP (1) EP2996695B1 (en)
JP (1) JP6366693B2 (en)
KR (1) KR102241198B1 (en)
CN (1) CN105307662B (en)
AU (1) AU2014265293B2 (en)
BR (1) BR112015028764B1 (en)
CA (1) CA2912682C (en)
CL (1) CL2015003357A1 (en)
CR (1) CR20150648A (en)
EA (1) EA035301B1 (en)
HK (2) HK1217294A1 (en)
IL (1) IL242605B (en)
MA (2) MA46490A1 (en)
MX (1) MX2015015782A (en)
MY (1) MY186547A (en)
NZ (1) NZ714927A (en)
PE (1) PE20160120A1 (en)
PH (1) PH12015502588A1 (en)
SG (1) SG11201509424VA (en)
UA (1) UA123533C2 (en)
WO (1) WO2014186637A1 (en)
ZA (1) ZA201509056B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34824A (en) 2012-05-25 2013-11-29 Janssen R & D Ireland NUCLEOSIDES OF URACILO SPYROOXETHANE
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
CA2927010C (en) 2013-10-11 2022-06-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015200216A1 (en) * 2014-06-24 2015-12-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
MA41441A (en) * 2014-12-19 2017-12-12 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES OF THEM
KR20230130175A (en) 2014-12-26 2023-09-11 에모리 유니버시티 N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP2018529777A (en) * 2015-09-29 2018-10-11 ヤンセン ファーマシューティカルズ インコーポレイテッド Combination therapy regimen for the treatment of HCV
WO2018017994A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination drug treatment for hepatitis c infection
CN108424431B (en) * 2017-09-06 2021-04-20 上海兆维科技发展有限公司 Preparation method of alpha-uridine
EP3684374A4 (en) * 2017-09-21 2021-06-16 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CN111372592A (en) 2017-12-07 2020-07-03 埃默里大学 N4-hydroxycytidine and derivatives and antiviral uses related thereto
KR20200140274A (en) * 2018-03-07 2020-12-15 에모리 유니버시티 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN112142809B (en) * 2020-09-29 2022-03-22 佛山科学技术学院 Uretidine dipropionate phosphoramidate compound, pharmaceutical composition thereof, and preparation method and application thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (en) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Antibacterial compounds, use and preparation thereof
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
TR199802136T2 (en) 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated Ire derivatives as inhibitors of the �MPDH enzyme.
EA001915B1 (en) 1996-10-18 2001-10-22 Вертекс Фармасьютикалз Инкорпорейтед Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AU743411B2 (en) 1998-08-21 2002-01-24 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
BR9913406A (en) 1998-09-04 2002-01-29 Viropharma Inc Process of treatment of infection caused by at least one virus of the family flaviviridae and of disease associated with said infection in a living host having said infection
BR9913935A (en) 1998-09-25 2001-06-19 Viropharma Inc Methods of treatment and prevention of infection caused by at least one virus of the family of flaviviridae and disease associated with said infection in a living host
EE200100492A (en) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated IMPDH inhibitors
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
AP1753A (en) 2001-06-11 2007-07-18 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavvivirus infection
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (en) 2001-06-26 2004-06-16 Japan Tobacco Inc THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS
JP4558314B2 (en) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド Viral polymerase inhibitor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
DE60221875T2 (en) 2001-11-02 2007-12-20 Glaxo Group Ltd., Greenford 4- (6-LOW) HETEROARYL ACYL-PYRROLIDINE DERIVATIVES AS HCV INHIBITORS
EP1440070A1 (en) 2001-11-02 2004-07-28 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
US20050009873A1 (en) 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
AU2003269890A1 (en) 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20050020884A1 (en) 2003-02-25 2005-01-27 Hart Charles C. Surgical access system
EP1617848A2 (en) 2003-04-25 2006-01-25 Gilead Sciences, Inc. Anti-cancer phosphonate conjugates
AU2004235848B2 (en) * 2003-05-09 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
SI2604620T1 (en) * 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modified fluorinated nucleoside analogues
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP4902361B2 (en) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ HCVNS-3 serine protease inhibitor
EP1828145A4 (en) 2004-12-10 2009-08-19 Univ Emory 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
EP1928475B1 (en) * 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8071568B2 (en) 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110104074A (en) * 2008-12-23 2011-09-21 파마셋 인코포레이티드 Synthesis of purine nucleosides
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2596004B1 (en) 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN103209987B (en) * 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
MX350809B (en) * 2011-12-20 2017-09-20 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication.
US9296778B2 (en) * 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2014099941A1 (en) * 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
SG11201504554UA (en) * 2012-12-21 2015-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11485753B2 (en) 2012-12-21 2022-11-01 Janssen Pharmaceutica Nv Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
KR20160040141A (en) 2016-04-12
HK1219900A1 (en) 2017-04-21
PE20160120A1 (en) 2016-02-24
SG11201509424VA (en) 2015-12-30
PH12015502588B1 (en) 2016-02-29
MA38675A1 (en) 2017-12-29
AU2014265293B2 (en) 2019-07-18
KR102241198B1 (en) 2021-04-15
JP6366693B2 (en) 2018-08-01
CA2912682C (en) 2021-07-06
MA46490A1 (en) 2021-04-30
US9895442B2 (en) 2018-02-20
MX2015015782A (en) 2016-06-02
BR112015028764A2 (en) 2017-07-25
PH12015502588A1 (en) 2016-02-29
EP2996695A4 (en) 2016-12-14
WO2014186637A1 (en) 2014-11-20
BR112015028764B1 (en) 2022-09-27
EA201592184A1 (en) 2016-04-29
NZ714927A (en) 2020-09-25
EA035301B1 (en) 2020-05-26
HK1217294A1 (en) 2017-01-06
ZA201509056B (en) 2016-11-30
CA2912682A1 (en) 2014-11-20
CR20150648A (en) 2016-03-09
CN105307662B (en) 2019-06-04
CN105307662A (en) 2016-02-03
JP2016518453A (en) 2016-06-23
MY186547A (en) 2021-07-26
US20140341847A1 (en) 2014-11-20
UA123533C2 (en) 2021-04-21
EP2996695A1 (en) 2016-03-23
IL242605B (en) 2018-08-30
EP2996695B1 (en) 2022-04-13
AU2014265293A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
CL2015003357A1 (en) 4'-Fluoro-2'-methyl substituted nucleoside derivatives
CL2016000153A1 (en) Glioxamide substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis b
CL2018000542A1 (en) New phenoxymethyl derivatives.
CL2015003395A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CL2016001120A1 (en) Compounds derived from pyrrolo1,2-f1,2,4triazine, a pharmaceutical composition that comprises them and their use in the treatment of a syncytial virus infection intermediary compounds. pct
CL2016002735A1 (en) Imidazo [4,5-c] quinolin-2-one compounds and their use to treat cancer
DOP2015000219A (en) HETEROARILO COMPOUNDS AND ITS USES
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
CL2015002394A1 (en) Histone Demethylase Inhibitors
CL2016000381A1 (en) Antiviral compounds
CL2016001509A1 (en) Crystal forms of antiviral sofosbuvir analogs
CL2015003615A1 (en) Substituted nucleosides, nucleotides and analogs thereof.
UY35485A (en) HETEROCYCLIC COMPOUNDS AND USES OF THE SAME
BR112016003229A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND OR A PHARMACEUTICAL COMPOSITION
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CL2008002893A1 (en) Substituted n-phenyl- (pyridin-3-yl) acetamide derivative compounds; pharmaceutical composition; preparation procedure; and its use to prevent or treat cancer.
CL2015003019A1 (en) Biaromatic antibacterial derivatives
CL2011000846A1 (en) Heterocyclic Substituted Compounds; pharmaceutical composition; and its use for the treatment of hepatitis c.
BR112016012146A2 (en) COMPOUNDS OF AMINOPYRIDINE DERIVATIVES AS KINASE INHIBITORS OF THE TAM FAMILY, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND THERAPEUTIC USE THEREOF
GT201500235A (en) ESTRA -1,3,5 (10), 16- TETRAENE -3-CARBOXAMIDS FOR THE INHIBITION OF THE 17B-HYDROXIESTEROID DEHYDROGENASE (AKR1C3)
CL2016000597A1 (en) Derivatives of deoxino jirimicina and its methods of use.
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
DOP2016000170A (en) COMPOUNDS DERIVED FROM HYDROXIFORMAMIDE AND USES OF THE SAME
CL2016002151A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
CR20150649A (en) DERIVATIVES OF NUCLEOSIDS 4´-AZIDO, 3´-DESOXI-3´-REPLACED FLUORO